Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CCR3 | P51677 | 4/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13551812 | 0.85 | TACR3 (0.61) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13873798 | 0.82 | SMN1; SMN2 (0.57) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL13873630 | 0.79 | SMN1; SMN2 (0.63) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13873636 | 0.78 | MEN1 (0.61) | SMN1; SMN2MEN1KMT2ACCR3 | |
| SCHEMBL4775057 | 0.78 | SMN1; SMN2 (0.63) | SMN1; SMN2MEN1KMT2ACCR3ALDH1A1 | |
| SCHEMBL24449599 | 0.78 | GLA (0.53) | SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL13873044 | 0.77 | MEN1 (0.67) | SMN1; SMN2MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13873199 | 0.77 | SPR (0.54) | SMN1; SMN2MEN1KMT2ACSNK1EALDH1A1 | |
| SCHEMBL4958207 | 0.77 | MEN1 (0.65) | SMN1; SMN2MEN1KMT2ACCR3LMNA | |
| SCHEMBL13873803 | 0.76 | MEN1 (0.56) | SMN1; SMN2MEN1KMT2ACCR3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | SMN1; SMN2 4277/4885MEN1 4174/4885KMT2A 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.